Chen A. CD19 And CD22 Dual-Target CAR-T Therapy Via CRISPR/Cas9 Engineering for Relapsed B-Cell Acute Lymphoblastic Leukemia. AJST. 2025;18(1):621-625. doi:10.54097/79zwp242